The immunosuppressive effect of mycophenolic acid (MPA) is essentially attributed to IMPDH II inhibition, which leads to a reduction of lymphocyte proliferation. We investigated the action of the MPA metabolites MPA-phenyl-glucuronide (MPAG) and MPAacyl-glucuronide (AcMPAG) on recombinant human IMPDH II (rhIMPDH II), as well as their passage into lymphocytes in vitro.
catalyzes the oxidation of inosine-5Ј-monophosphate (IMP) to xanthosine-5Ј-monophosphate (XMP) with concomitant reduction of nicotinamide adenine (NAD ϩ ) to NADH (1 ) . Two IMPDH proteins are encoded by 2 distinct genes, namely IMPDH I and IMPDH II (2 ) . Both genes code for 514 -amino acid proteins, showing 84% homology with one another (2, 3 ) . The reaction catalyzed by IMPDH II, the 3-dimensional structure of which has recently been published (4 ) , is a rate-limiting step in the de novo biosynthesis of guanine and deoxyguanine nucleotides (5, 6 ) . Leukocytes are devoid of the alternative (socalled salvage) pathway that takes place in other cells to recycle unused nucleotides. Therefore, leukocytes are strongly dependent on this de novo pathway (6 ) to produce guanine nucleotides, which are essential for normal cell proliferation and function. Moreover, IMPDH II has been reported to be specifically upregulated in proliferating lymphocytes (7 ) . Based on this knowledge, IMPDH II has been aimed as a target for immunosuppressive drugs (8 ) .
Mycophenolic acid (MPA) is an uncompetitive IMPDH II inhibitor (9 ) , effective in the prevention of acute rejection in allograft recipients (10, 11 ) . MPA binds to the enzyme-XMP (E-XMP*) intermediate complex and prevents its hydrolysis and thus the release of XMP (1 ) . As a consequence, MPA inhibits T and B lymphocyte proliferation and compromises their function (9, 12, 13 ) .
The major metabolite of MPA, MPA-phenylglucuronide (MPAG), does not inhibit IMPDH II (14 ) . A second metabolite, AcMPAG (acyl-MPAglucuronide), is an uncompetitive IMPDH II inhibitor (15 ) whose exact mechanism of inhibition may differ from that of MPA. Covalent protein binding has been described for numerous acyl-glucuronides, and AcMPAG could bind covalently to IMPDH II, inducing irreversible inhibition of the enzyme (16 ) . Regardless of the mechanism involved, it is not clear whether this putative pharmacological activity of AcMPAG could substantially contribute to the immunosuppressive effect of MPA.
There is significant interindividual pharmacokinetic variability in patients treated with mycophenolate mofetil (17) (18) (19) . Subtherapeutic exposure to MPA in transplant recipients is associated with a significantly higher incidence of acute rejection (20 -22 ) , whereas excess exposure leads to leukopenia and anemia (23 ) , highlighting the need for therapeutic drug monitoring and area under the curve (AUC) evaluations of MPA (21, 24 -27 ) .
Methods for quantifying plasma or serum MPA include HPLC-ultraviolet, HPLC-mass spectrometry, HPLC-tandem mass spectrometry (HPLC-MS/MS) (28 ), enzyme-multiplied immunoassay (Emit; DadeBehring), and enzyme inhibition assay (TMPA kit; Roche Diagnostics). The Emit overestimates the MPA concentration by 16% up to 80% when MPA is combined with cyclosporine (28, 29 ) , a result attributed to cross-reactivity with acyl-MPA-glucuronide (30 ) . The newest version of this kit tends to correct the problem. If AcMPAG has immunosuppressive activity in vivo, it may deserve to be monitored for MPA dose adjustment. The Roche kit is based on rhIMPDH II activity, and therefore should theoretically account for all compounds in plasma that inhibit IMPDH II. However, an international validation study of this kit (31 ) found that AcMPAG cross-reacted only 5% with rhIMPDH II, which was confirmed in patients' samples, for which this assay yielded nearly identical results to LC-MS/MS, which selectively measures MPA.
In this study we evaluated the potential inhibition of rhIMPDH II by MPAG and AcMPAG compared to MPA, and also the potential of MPA and its metabolites to cross the lymphocyte cell membrane ex vivo to estimate their abilities to inhibit IMPDH II in vivo.
Materials and Methods

CHEMICALS AND REAGENTS
Roche Diagnostics kindly provided the rhIMPDH II used in this study. Tris-HCl, KCl, EDTA, NAD ϩ , IMP, dithiothreitol, and MPA were obtained from Sigma; MPAG was purchased from Analytical Services International Ltd.; and AcMPAG was a gift from HoffmannLa Roche Ltd. We prepared a 1-g/L stock solution of AcMPAG in acetonitrile and checked its purity by LC-MS/MS, which showed no MPA nor any visible chromatographic peak having an ion composition compatible with MPA-derived compounds.
rhIMPDH II ENZYME ASSAY
The rhIMPDH II assay was performed in 100 mmol/L Tris-HCl buffer (pH 8 at 37°C), containing 100 mmol/L KCl, 2 mmol/L EDTA, and 1 mmol/L dithiothreitol. We added a volume of 100 L rhIMPDH II (4% vol/vol) to 850 L enzyme buffer and vortexmixed it thoroughly with 20 L IMP (0.01-10 mmol/L). The reaction medium was prewarmed at 37°C using an incubator block. We added 10 L potential inhibitors (MPA, AcMPAG, or MPAG) diluted in acetonitrile (final percentage 1% vol/vol) to the incubation mixture. Control incubations were spiked with the same amount of acetonitrile. We then started the reaction by adding 20 L NAD ϩ (0.25-20 mmol/L). The mixture was immediately mixed thoroughly, transferred into a 1-mL UV microvial, and placed in a thermoregulated spectrophotometer (Shimadzu UV 1202). As the rhIMPDH II catalyzed reaction is equimolar, NADH formation is directly linked to the amount of IMP and NAD ϩ used. Reaction monitoring consisted of spectrophotometric measurement of NAD ϩ reduction (molar absorptivity 6220 at ϭ 340 nm). Two measurements per second were performed for 5 min. We computed the results using an in-house program that calculates the initial velocity rate of each reaction using a linear regression model.
To test AcMPAG and MPAG stability during the assay, both molecules were separately incubated in triplicate at 2 different concentrations (10 g/L and 10 mg/L) in 1 mL of the reaction mixture at 37°C for 30 min. Every 5 min, 100 L was sampled, mixed with 100 L acetonitrile/formic acid (97%/3% vol/vol), and immediately chilled on ice to avoid further degradation. Negative controls were carried out in triplicates by incubating AcMPAG and MPAG in water at 37°C at the same concentrations. MPA, AcMPAG, and MPAG were then determined in each sample using a validated HPLC-MS/MS method (32 ) .
KINETIC EXPERIMENTS
To calculate the kinetic parameters of rhIMPDH II reaction with each cosubstrate (NAD ϩ and IMP), 6 increasing concentrations of NAD ϩ (5-400 mol/L) and IMP (2-200 mol/L) were incubated as described above, with fixed saturating concentrations of IMP (200 mol/L) or NAD ϩ (400 mol/L), respectively. The initial velocity was calculated for each reaction using linear regression. The other kinetic parameters were esti-mated with a Michaelis-based nonlinear regression model using Winreg 3.1 software (Jean Debord, Limoges University Hospital http://www.unilim.fr/pages_perso/jean. debord/winreg/winreg1.htm).
INHIBITION EXPERIMENTS
rhIMPDH II was incubated in triplicate as described above with a saturating concentration of both cosubstrates (IMP 200 mol/L; NAD ϩ 400 mol/L) and 10 increasing concentrations of the 3 potential inhibitors: MPA (1 g/L to 1 mg/L), AcMPAG (10 g/L to 10 mg/L), and MPAG (200 g/L to 20 mg/L). We calculated the half-maximal inhibitory concentration (IC 50 ) for each potential inhibitor using the Hill model and Winreg 3.1.
To calculate the inhibition constant (K i ) with respect to both IMPDH II cosubstrates NAD ϩ and IMP, each inhibitor was incubated at 5 increasing concentrations (50 g/L to 3.0 mg/L for AcMPAG and 1 g/L to 1.0 mg/L for MPA). We first performed experiments at a fixed saturating concentration (200 mol/L) of IMP and increasing concentrations of NAD ϩ (5-400 mol/L), then performed at a saturating NAD ϩ concentration (400 mol/L) and 6 increasing concentrations of IMP (2 mol/L to 200 mol/L). We calculated the K i of each inhibitor for each cosubstrate by nonlinear regression using inhouse software called Inhib 1.1 (Jean Debord, CHU Limoges).
To compare the effect on rhIMPDH II of AcMPAG alone or in the presence of MPA, AcMPAG was incubated with rhIMPDH II at concentrations ranging from 0.05-to 10-fold the MPA IC 50 value, with MPA or AcMPAG at approximately its IC 50 (25 g/L and 300 g/L, respectively). The inhibition rates were calculated with respect to a positive control without any inhibitor.
CAPACITY OF AcMPAG AND MPA TO CROSS CELLULAR
MEMBRANES
We cultured Jurkat cells from a human cell line of lymphoma in a 75-cm 2 culture flask at a concentration of 2 ϫ 10 6 cells/mL in RPMI 1640 medium supplemented with 10% FBS, 2 mmol/L glutamine, 1% amino acids, 1% vitamins, 1% pyruvate, 100 U/mL penicillin, and 100 mg/L streptomycin. Incubations were performed at 37°C and 5% CO 2 for 6 h with MPA (final concentration 20 mg/L), AcMPAG, and MPAG (taken here as a chemically stable control for AcMPAG; final concentration 2 mg/L). The medium was then centrifuged; the supernatant was sampled and analyzed to measure the extracellular concentration, and the cell pellet was used to measure the intracellular concentration after lysis by addition of 200 L of a 50/50 (vol/vol) hypotonic water/ formic acid solution and incubation at Ϫ20°C for 48 h. We quantified MPA, MPAG, and AcMPAG using a published LC-MS/MS technique (32 ). The limit of quantification of the technique was 10 g/L. The linearity was verified up to 10 mg/L (r ϭ 0.999). The intraassay CVs were Ͻ10% and the interassay CVs Ͻ15% over this linearity range (32 ) . The recovery was good, with mean relative errors Ͻ15% over the linearity range.
We could not calculate the actual intracellular concentration because the volume of intracellular medium, or even the cells' volume or mass, cannot be precisely measured. Therefore, we calculated the ratio of the drug amount found in the cells after 6 h of incubation (in g) to the total amount of compound present in the incubation medium at time 0 (e.g., the spiked amount), to compare the cell passage of AcMPAG relative to those of MPA and MPAG.
Results and Discussion
AcMPAG AND MPAG STABILITY IN ENZYMATIC BUFFER
Within the first 5 min of incubation (corresponding to the rhIMPDH II assay reaction time), no substantial variation of the AcMPAG concentration was observed in the incubation buffer. However, prolonged incubation was associated with clear AcMPAG degradation: after 30 min in the incubation buffer, about 20% of AcMPAG had disappeared, whereas no degradation was observed in the negative control (incubation in water) (Fig. 1) . MPA production was not detected after AcMPAG degradation, despite the use of an LC-MS/MS method with a limit of quantification of 10 g/L. We found a minute chromatographic peak with common transitions observed with AcMPAG but with a slightly shorter retention time (so it was not integrated together with AcMPAG). This peak might correspond to one or more of the previously described positional isomers of MPAG (2-O-␤ isomer, 3-O-␤ isomer, and 4-O-␤ isomer) (32, 33 ) ; however, little is known about these compounds. As the AcMPAG concentration showed no considerable variation in the first 5 min of stability experiments, we assumed that these particular isomers would be present in a very small amounts during the 5 min of the enzymatic reaction. MPAG was stable in the enzymatic buffer for 30 min, regardless of its concentration (Fig. 1) . However, a small and stable amount of MPA (about 100 g/L) was found for the highest MPAG concentration tested (10 mg/L), throughout the experiment.
rhIMPDH II KINETICS
Human recombinant rhIMPDH II kinetic profiles were reproducible and well-fitted with the Michaelis model ( Fig. 2A and B by Analytical Services International Ltd. reportedly contained 0.9% residual MPA. In particular, the residual MPA concentration at the MPAG IC 50 (i.e., 3.3 mg/L) was 23.1 g/L, close to the MPA IC 50 . This, in itself, could explain the observed inhibition of IMPDH II by MPAG solutions, as pointed out by Korecka et al. (34 ) . Inhibition of rhIMPDH II by MPA and AcMPAG was described by an uncompetitive model with a high statistical confidence (r 2 ϭ 0.99; P Ͻ 0.001). The respective K i values calculated at saturating concentrations of IMP and NAD ϩ are given in Table 1 . AcMPAG had approximately an 8-fold higher K i than MPA, that is to say a weaker affinity for IMPDH II. As explained above, however, it is possible that a small fraction of AcMPAG (Ͻ5%) had been transformed into 2-O-␤, 3-O-␤, and/or 4-O-␤ MPAG isomers during the 5-min incubation in the enzymatic buffer. Thus, the measured K i could be a combination of the actual AcMPAG K i and those of its isomers. Nevertheless, the concentrations of the isomers were probably very low compared to that of AcMPAG and contributed minimally (if any) to the measured K i value. Although no extra peak with the same ion transitions as MPA or AcMPAG was visible in the enzymatic inhibition experiments, a minor peak yielded the same ion transitions as AcMPAG, but with a slightly shorter retention time, in the 30-min stability experiment and in the 6-h incubation experiments with Jurkat cells, which might correspond to one or more of these metabolites. In the absence of standard compounds, it was impossible to measure the actual concentrations of these isomers. Their contribution to IMPDH II inhibition in the present experiments seems not to be relevant.
The incubation procedure, buffer, and experimental conditions used here were very close to those used in published articles (1, 35 ) , which reported consistent, though different, K i values (9.6 nmol/L and 3.9 nmol/L, respectively). The differences could probably be explained by the source and nature of the recombinant enzyme used. Both studies purified IMPDH II from a strain of E. coli transfected with a plasmid containing the IMPDH II gene, whereas ours was provided by Roche Diagnostics without information about the method of production or purification. To evaluate the actual influence of AcMPAG on rhIMPDH II activity in presence of MPA, we performed coincubation experiments. The left bars shown in Fig. 4 represent residual rhIMPDH II activity when coincubated with 25 g/L MPA (close to the IC 50 ) plus increasing AcMPAG concentrations ranging from 1.25 to 250 g/L (1/20, 10-fold the MPA concentration). The right bars show the residual rhIMPDH II activity using AcMPAG IC 50 (300 g/L) instead of MPA as baseline inhibition, on top of which the same increasing AcMPAG concentrations were added. No notable variation in rhIMPDH II residual activity was observed by the addition of small amounts of AcMPAG from 1.25 to 10 g/L (AcMPAG/MPA ratios of 1/20 -1/2.5, covering the usual range of in vivo plasma ratios), compared to IC 50 alone, when coincubated with either MPA IC 50 or AcMPAG IC 50 . For AcMPAG concentrations Ն25 g/L, an additional effect of AcMPAG was observed with respect to the baseline 50% inhibition in both experiments, with numerically but not statistically lower inhibition in the MPA group (ANOVA test, P ϭ 0.09).
INTRACELLULAR MPA AND AcMPAG CONCENTRATIONS AND EXPECTED EFFECTS ON IMPDH II ACTIVITY
We first checked the stability of MPA and its metabolites under the experimental conditions using the lymphoma cell culture. As before with the enzymatic buffer, the MPAG concentration remained unchanged in the supplemented RPMI medium, MPA showed a small decrease of about 5%, and AcMPAG, which is much more unstable, showed a 50% decrease in concentration after 6-h incubation. 
